have been reported to respond to ICI-based immunotherapy only once previously administered a low dose (10 mg/kg) but not an ultralow (5 mg/kg) or high (20 mg/kg) dose of oxaliplatin, culminating in improved tumor infiltration by CD8+ CTLs, superior secretion of interferon gamma (IFNG), and consequently long-term disease control associated with the development of immunological memory [27]. The gene discussed is CD8A; the disease is neoplasm.